Results 121 to 130 of about 137,652 (287)

Genetic Determinants of Treatment‐Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Osteonecrosis and fractures are serious corticosteroid‐induced bone toxicities in children treated for acute lymphoblastic leukemia, yet their genetic determinants remain incompletely defined. In this study, we aimed to identify novel genetic contributors to bone toxicity and to evaluate the robustness of both newly identified and previously ...
Rachid Abaji   +14 more
wiley   +1 more source

Elimination Profile of Deflazacort and Metabolites in Urine and Plasma Following Oral Administration: Relevance to Sports Drug Testing

open access: yesDrug Testing and Analysis, EarlyView.
Results confirm that the MRL of 30 ng/mL for 21‐desacetyl‐deflazacort together with a 3‐day washout period is an appropriated strategy to detect oral deflazacort administration in sport competition. ABSTRACT Deflazacort (DEF) is a glucocorticoid prohibited in sports competitions when orally administered.
Sergi Coll   +5 more
wiley   +1 more source

Using controlled laser-microporation to increase transdermal delivery of prednisone

open access: yes, 2010
The objective was to investigate whether laser microporation could enhance transdermal delivery of prednisone. Results demonstrated that transport was controlled by pore number and depth; it was substantially improved over delivery through intact skin ...
Bachhav, Yogeshwar   +13 more
core   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

open access: yes, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

The Nonlinear Pharmacokinetics of Prednisone and Prednisolone (Metabolism, Glucosteroids).

open access: yes, 1984
Prednisone and prednisolone are synthetic glucocorti-costeroids useful in the treatment of various disease states. Both drugs have been shown to obey nonlinear pharmacokinetics in man and some animals.
Ferry, James Joseph, Jr.
core  

Prenatal betamethasone–postnatal N‐methyl‐D‐aspartic acid model of spasms: Update on mechanisms and treatments

open access: yesEpilepsia Open, EarlyView.
Abstract Infantile epilepsy spasms syndrome (IESS), formerly known as infantile spasms or West Syndrome, is a severe epilepsy syndrome affecting about 3 in 10,000 newborns in the United States. Characterized by clusters of epileptic spasms, interictal hypsarrhythmia, and developmental delays, IESS has diverse causes, including structural‐metabolic ...
Kayla Vieira   +5 more
wiley   +1 more source

CAQ Corner: Immune‐mediated complications

open access: yes, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

The multiple hit model of infantile and epileptic spasms: The 2025 update

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou   +6 more
wiley   +1 more source

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3+/D120N mouse model of Lennox–Gastaut syndrome

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Lennox–Gastaut syndrome (LGS) is a drug‐resistant developmental and epileptic encephalopathy (DEE). Preclinical drug development for LGS is constrained by a lack of syndrome‐relevant animal models. We aimed to evaluate a Gabrb3+/D120N knock‐in (KI) mouse model of LGS by quantifying atypical absence seizures and epileptic spasms and ...
Thomas Harman   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy